

五鼎生技
APEXBIO
T a i w a n

2022 1Q

2022 Jun

APEXBIO

Company profile

| | |
|---------------------|--|
| Stock # | TSEC 1733 |
| Industry | IVD Medical Device |
| Operation Locations | <p>Head quarter: No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan</p> <p>Tao Yuan Factory: No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Taoyuan City 337, Taiwan</p> <p>Suzhou Corp.: Room 106, No.2, Kecheng Road, SIP, Suzhou, China</p> <p>Omnis Health LLC : 1736 River Hills Dr Suite 6, Nashville, TN 37210,USA</p> |
| Started | 12/02/1997 |
| IPO | 06/13/2000(4101 OTC) 09/17/2001(1733 TSEC) |
| Capital | NTD 1 Billion |
| Chairman/CEO | Thomas Shen PhD |
| Employees | 693 people (upto 3/31/2022) |

Milestone

1997 ApexBio set-up
1998 BGM FDA 510K approval
1999 Uric Acid patent granted
2000 IPO listed to Taiwan OTC
2001 Transit IPO listed to TSEC

2007 Lactate launch
2008 Voice BGM launch
2009 Taoyuan factory set-up
2010 Tele-health tech build-up
2011 AEO certified by Customs Admin

2017 Acquired Omnis Health LLC
Brazil ANVISA notified
2018 ivCGM production set-up
Ket-1 FDA 510K approval
2019 ISO45001:2018 notified
2020 GCTU CE approval

1997-2001

2002-2005

2006-2011

2012-2015

2016-2020

2002 ISO 9001/13485 notified
2003 CE IVDD notified
2005 Pesticide residues check
product launch


2012 ApexBio Suzhou Corp set-up
2013 1st Taiwan MITTELSTAND Award
from MOEA
2015 HbA1C/MultiSure GK products launch
APEA Award Outstanding Category
ISO14001/OHSAS18001 notified

Quality system

| Region | The Authority | Regulatory compliance |
|--------|---------------|--|
| Taiwan | TFDA | GMP |
| EU | CE | ISO 13485:2016 CE mark number:CE0197 EN ISO 15197:2015 |
| USA | FDA | 510K's FDA on-site audit w/o 483 citations 2001/2006/2011/2016 |
| China | CFDA | Medical Device Class II |
| Japan | PMDA | |
| Brazil | ANVISA | 2017 passed on-site audit |

ESH policy

In response to environmental protection and occupational safety and health policies, management procedures have been established year by year to consistently comply with the GRI guidelines in order to achieve the goal of sustainable of enterprises.



Product portfolio

Blood glucose monitoring systems



Professional Monitoring systems



■ Uric Acid ■ Hemoglobin ■ Lactate ■ Ketone ■ HbA1C

Multi-functional systems



■ Glucose + Uric Acid

■ Glucose + Ketone

■ Glucose + Cholesterol

■ Glucose + Cholesterol + TG + Uric Acid



GLUCOSURE POC

Glucose/Ketone POC barcode scanner + wifi

KETOSURE™ POC

BLOOD KETONE MONITORING SYSTEM

Ketone POC barcode scanner + wifi




行動推車
操作者ID/患者ID



試片批號
支援1維/2維條碼



POC平台
血糖管理系統



Hospital

Eclipse PLUS

Eclipse PLUS

MULTI-PURPOSE ANALYZER

- Hemoglobin A1c
- Microalbumin
- Creatinine
- Albumin Creatinine Ratio (ACR)



Specifications

- Display: 5" Full Color LCD
- Display Unit:
 - HbA1c: %, mmol/mol, eAG
 - Microalbumin: mg/dL
 - Creatinine: mg/dL, mmol/L
 - ACR: mg/g, mg/mmol
- Operating/User Interface: Touch Panel Screen
- Data Port: Type-A USB
- Power Supply: 100~240V, 50/60Hz
- Dimension: 290L x 206W x 137H (mm)
- Weight: 1.6kg
- Operating Condition:
 - Temperature: 18~35°C/Humidity: <80%
- Analyzer Storage Condition:
 - Temperature: 4~50°C/Humidity: <80%
- Cartridge Storage Temperature:
 - HbA1c: 2~8°C
 - Microalbumin: 4~30°C
 - Creatinine: 4~30°C
 - ACR: 4~30°C
- Accessories: Optical Control Cartridge, Barcode Scanner, Printer, USB Cable, Power Adaptor




APEX BIOTECHNOLOGY CORP.,
No. 7, Li-Hsin 5th Rd., Hsinchu Science Park,
Hsinchu, Taiwan
Tel: 886-3-6641852 / Fax: 886-3-6676302
E-mail: info@apexbio.com / Website: www.apexbio.com



Eclipse PLUS

MULTI-PURPOSE ANALYZER




APEXBIO

For Clinic
and Hospital

APEXBIO

Customized projects

- Product platform focus on electrochemistry/photometry/immunology
- To derive new parameter tests and optimize our core platform.
- Sharing our advantage of regulation/quality control/sales channels/clinical trails/manufacturing to alliance with partners and customers.
- Integrate to IOT with hospitals and healthcare service centers
- Cooperation with customer for ivCGM (ICU use)



Global sales distribution



| Territory | 2020 | 2021 | 2022/1Q |
|----------------|------|-------|---------|
| America | 42% | 43.5% | 37% |
| EU | 46% | 45% | 55% |
| Asia | 11% | 11% | 8% |
| Africa | 1% | 0.5% | -- |


Finance Performance

| | 2020 | 2021 | 2022/1Q |
|------------------------------------|-----------|-----------|---------|
| Revenue | 2,005,337 | 2,132,656 | 521,954 |
| Gross margin | 452,224 | 571,512 | 132,305 |
| Operation profit | 103,328 | 204,949 | 39,740 |
| Profit after tax | 94,629 | 202,289 | 45,487 |
| EPS | 0.95 | 2.03 | 0.46 |
| G/M ratio | 22% | 27% | 25% |
| Shipped Meter Qty (kit) | 1,731K | 1,677K | 453K |
| Shipped Strip Qty(pcs) | 1,061M | 1,167M | 299M |

Product ratio


2021

■ BGM & A1C ■ Electrode
■ Non-BGM ■ Others



2022/ 1Q

■ BGM & A1C ■ Electrode
■ Non-BGM ■ Others



Non-BGM

Hemoglobin/Ketone/UricAcid/Lactate/Cholesterol/
Pesticide quick check etc

the 8th Corporate Governance Evaluation (2021)

| Category | Total number of indicators | | weighting | | Points for satisfied indicators | | Number of inapplicable indicators | | Extra Credit Indicators: | |
|---|----------------------------|------|-----------|------|---------------------------------|------|-----------------------------------|------|--------------------------|------|
| | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 |
| Protecting Shareholder Rights and Interests and Treating Shareholders Equitably | 16 | 16 | 0.19 | 0.2 | 14 | 15 | 0 | 0 | 0 | 0 |
| Enhancing Board Composition and Operation | 28 | 26 | 0.34 | 0.33 | 20 | 22 | 0 | 0 | 3 | 3 |
| Increasing Information Transparency | 21 | 21 | 0.26 | 0.26 | 12 | 13 | 0 | 0 | 0 | 0 |
| Putting Corporate Social Responsibility into Practice | 17 | 16 | 0.21 | 0.21 | 15 | 14 | 0 | 0 | 3 | 1 |
| others | 2 | 2 | - | - | - | - | - | - | - | - |

Total score : 85.14

Ranking (SEC): 21%~35%

Thank you